Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 2015

View Archived Issues

Col-Treg designated by the FDA as orphan drug for the treatment of chronic non-infectious uveitis

Promising phase II results on lenvatinib in advanced medullary thyroid cancer

TC Biopharm granted CTA approval to treat cancer patients with ImmuniCell

Protalix reports positive data from second dose cohort in phase I/II trial of PRX-102

NCI grant supports planned phase II study of Yeliva for refractory or relapsed multiple myeloma

New approaches identified for Middle-East respiratory syndrome coronavirus vaccination

Next-generation CDK2/9 inhibitor CCT-68127 shows potent activity against lung cancer cells

Phase I findings confirm bioavailability of Gordagen's MELT3 formulation

FDA accepts IND and grants orphan drug designation to DTX-101 for hemophilia B

FDA grants fast track designation to MN-001 for IPF

Amgen seeks FDA approval for new delivery option for monthly administration of Repatha

AR-301 gets FDA fast track designation for acute pneumonia caused by S. aureus

Blueprint Medicines cleared to study BLU-285 in systemic mastocytosis

SK Biopharmaceuticals discovers dopamine reuptake inhibitors

Vaccibody starts phase I/IIa trial of VB10.16 in women with cervical intraepithelial neoplasia

Nimbus Lakshmi introduces TYK2 and JAK2 inhibitors

Gilead patent discloses compounds for the treatment of HIV

BioCancell's BC-819 receives FDA fast track designation in bladder cancer

Treventis reports beta-amyloid aggregation inhibitors

EMA grants orphan drug designation to Stemline's SL-401 for AML

FDA advisory committees recommend approval of Collegium's Xtampza ER

FDA approves Humira for moderate to severe hidradenitis suppurativa

HUHS-1015 potently inhibits malignant mesothelioma cell proliferation

FDA accepts first NDA for a digital medicine

Novel PI4K2A gene mutations identified in cutis laxa syndrome with choreoathetosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...